Walti, Carla S. http://orcid.org/0000-0002-0750-2543
Halpern, Anna B. http://orcid.org/0000-0002-4326-0748
Xie, Hu http://orcid.org/0000-0003-0556-6591
Kiem, Erika S.
Chung, E. Lisa
Schonhoff, Kelda G.
Huebner, Emily M.
Delaney, Colleen http://orcid.org/0000-0002-1044-2801
Liu, Catherine http://orcid.org/0000-0002-7532-4822
Pergam, Steven A.
Cheng, Guang-Shing http://orcid.org/0000-0003-4324-9634
Kimball, Louise E.
Leisenring, Wendy M. http://orcid.org/0000-0001-7405-0906
Boeckh, Michael
Walter, Roland B. http://orcid.org/0000-0002-9268-3341
Hill, Joshua A. http://orcid.org/0000-0002-7665-7100
Article History
Received: 4 September 2022
Revised: 30 November 2022
Accepted: 2 December 2022
First Online: 12 December 2022
Competing interests
: JAH received a research grant from Deverra Therapeutics (formerly Nohla Therapeutics) for support of the work. No other author received any support for the current work. CSW, HX, ESK, ELC, KMG, EMH, CL, LEK, and WML have nothing to disclose. ABH served as a consultant for Abvie and Agios and received research funding from Pfizer, Nohla Therapeutics, Jazz Pharmaceuticals, Imago Pharmaceuticals, Novartis, Bayer, Tolero Pharmaceuticals, Agios Pharmaceuticals, and Gilead. CD is scientific founder and CSO of Deverra Therapeutics. SAP received research funding from Chimerix, Inc., Global Life Technologies, Inc., Merck & Co., and participated in an NIH clinical trial where vaccines were provided by Sanofi Aventis. GSC served as a consultant to Janssen Pharmaceuticals. MB served as a consultant for AlloVir, Gilead, Merck, SymBio Pharmaceuticals, Vir Biotechnolgy, Helocyte (also options to acquire ownership interest), Evrys Bio (also options to acquire ownership interest), and GSK, and received research funding from Gilead, GSK, Janssen, Ansun Biopharma, Vir Biotechnology and Merck. RBW received laboratory research grants and/or clinical trial support from Agios, Amgen, Aptevo, Arog, BioLineRx, Celgene, ImmunoGen, Janssen, Jazz, Kura, MacroGenics, Pfizer, Selvita, and Stemline; has ownership interests in Amphivena; and is (or has been) a consultant to Agios, Amgen, Amphivena, Aptevo, Astellas, BioLineRx, Boston Biomedical, Bristol Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Jazz, Kite, Kronos, MacroGenics, New Link Genetics, Pfizer, and Race. JAH served as a consultant for Gilead, Amplyx, AlloVir, Allogene therapeutics, CRISPR therapeutics, CLS Behring, PtumHealth, Octapharma, and Takeda, and received research funding from Gilead, AlloVir, and Takeda.